See today's BioWorld Science
To read the full story, subscribe or sign in.
Cancer

In situ CAR T receives IND clearance

Aug. 1, 2024
Umoja Biopharma Inc. has received clearance from the FDA to begin a first-in-human trial of its CAR T product UB-VV111. The company expects to dose the first patient by the end of 2024.
BioWorld Science Regulatory CAR T Cancer Cell therapy Immuno-oncology FDA IND